dronabinol has been researched along with Scleroderma, Diffuse in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Bloom, BJ; Chung, L; Constantine, S; de Vries-Bouwstra, J; Denton, CP; Dgetluck, N; Dinh, Q; Distler, O; Finzel, S; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Jankowski, T; Jun, JB; Kafaja, S; Khanna, D; Kuwana, M; Lee, EB; Leszcyzński, P; Levy, Y; Litinsky, I; Matucci-Cerinic, M; Mayes, M; Sandorfi, N; Simms, RW; Spiera, R; Steen, V; Stevens, W; White, B | 1 |
1 trial(s) available for dronabinol and Scleroderma, Diffuse
Article | Year |
---|---|
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Topics: Cannabinoid Receptor Agonists; Dronabinol; Humans; Scleroderma, Diffuse; Scleroderma, Systemic; Severity of Illness Index; Skin; Treatment Outcome | 2023 |